We're not just writing the script for Mediforum’s success story, we're going all-in on this groundbreaking trial. Making history as the first Korean pharma company to list on NASDAQ, and bringing us ever closer to a cure for dementia and Alzheimer's disea
Aducanumab, the latest drug approved by the FDA for the treatment of Alzheimer'sis estimated to cost $56,000 annually. According to the New York Times, "There’s little evidence that the drug, Aduhelm, slows the progression of dementia, but the Food and Dr
Brain One is a naturally derived supplement made from a combination of extracts to improve memory %26 concentration. Combining the natural compounds with four-year-aged Korean ginseng boosts the immune system, enhances platelet count, and increases blood
